Showing 4091-4100 of 5646 results for "".
- Altris Launches New Artificial Intelligence Platform for Automated OCT Scanshttps://modernod.com/news/altris-launches-new-artificial-intelligence-platform-for-automated-oct-scans/2481202/Altris Inc. announced the launch of Altris AI, an artificial-intelligence-powered software platform designed to automate OCT examination. The secure, cloud-based platform provides fast analysis and visualization of 100 pathologies and pathological signs, including rare ones, according to Altris.<
- DORC Acquires Peregrine Surgical and Completes Acquisition of the Remaining Stake in WEFIShttps://modernod.com/news/dorc-acquires-peregrine-surgical-and-completes-acquisition-of-the-remaining-stake-in-wefis/2481192/DORC announced the acquisition of Peregrine Surgical and the acquisition of the full ownership of WEFIS GmbH following an initial equity investment announced earlier in 2022. Financial terms of the deals were not disclosed. DORC says both acquisitions extend the productio
- Johnson & Johnson Vision Receives Approval in Canada for Acuvue Abiliti Overnight Therapeutic Lenses for Myopia Managementhttps://modernod.com/news/johnson-johnson-vision-receives-approval-in-canada-for-acuvue-abiliti-overnight-therapeutic-lenses-for-myopia-management/2481191/Johnson & Johnson Vision received approval from Health Canada for Acuvue Abiliti Overnight Therapeutic Lenses for Myopia Management. These orthokeratology (ortho-k) lenses are worn overnight for the control of myopia and are specifically designed to match a patient’s eye based on i
- Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual Meetinghttps://modernod.com/news/tarsus-to-present-additional-saturn-2-pivotal-phase-3-trial-data-at-the-american-academy-of-optometry-2022-annual-meeting/2481189/Tarsus Pharmaceuticals announced that additional efficacy results from the Saturn-2 pivotal phase 3 trial of TP-03 (lotilaner ophthalmic solution, 0.25%) in Demodex blepharitis patients will be presented at the upcoming American Academy of Optometry 2022 Annual Meeting in San D
- Genentech Voluntarily Recalls Susvimo Ocular Implant for Wet AMDhttps://modernod.com/news/genentech-voluntarily-recalls-susvimo-ocular-implant-for-wet-amd/2481185/Roche and Genentech announced a voluntarily recall of the Susvimo (ranibizumab injection) ocular implant for wet AMD, citing a manufacturing problem with the device. In addition, the companies announced that new implantations, including in ongoing global clinical trials, have been paused.
- Lori Tierney Joins Johnson & Johnson Vision as President of Americashttps://modernod.com/news/lori-tierney-joins-johnson-johnson-vision-as-president-of-americas/2481184/Johnson & Johnson Vision announced that Lori Tierney has joined the company as President of Americas. In this critical leadership role, Ms. Tierney will have full accountability for shaping the strategy and driving industry-leading growth of the vision care portfolio in both North America and
- Azura Ophthalmics Expands Broad Intellectual Property Portfolio to 12 US and European Patentshttps://modernod.com/news/azura-ophthalmics-expands-broad-intellectual-property-portfolio-to-12-us-and-european-patents/2481182/Azura Ophthalmics announced the company’s US 11,459,351 patent (the ‘351 patent) was granted by the US Patent and Trademark Office. This patent strengthens the company’s extensive portfolio protecting its use of dual-action keratolytic drug conjugates in developme
- OcuTerra Reports Publication of OTT166 Safety and Biological Activity Data From Phase 1b Study in Diabetic Eye Diseasehttps://modernod.com/news/ocuterra-reports-publication-of-ott166-safety-and-biological-activity-data-from-phase-1b-study-in-diabetic-eye-disease/2481180/OcuTerra Therapeutics announced the publication of a paper titled “The Safety and Biological Activity of OTT166, a Novel Topical Selective Integrin Inhibitor for the Treatment of Diabetic Eye Disease: A Phase 1b Study” in Ophthalmic Surgery, Lasers and Imaging Retina (
- Olleyes Announces Partnership With Tobii to Incorporate Advanced Eye Tracking Features Into VisuALL ETS Modelhttps://modernod.com/news/olleyes-announces-partnership-with-tobii-to-incorporate-advanced-eye-tracking-features-into-visuall-ets-model/2481178/Olleyes announces a partnership with Tobii to incorporate advanced eye tracking features within the VisuALL Virtual Reality Platform (VRP) ETS package. Tobii technology will further enhance the capabilities of the Olleyes VisuALL ETS to deliver a variety of ophthalmic tests with superior acc
- Oculis SA and European Biotech Acquisition Corp Announce Agreement to Create Nasdaq-Listed Biopharmaceutical Companyhttps://modernod.com/news/oculis-sa-and-european-biotech-acquisition-corp-announce-agreement-to-create-nasdaq-listed-biopharmaceutical-company/2481177/Oculis SA and European Biotech Acquisition Corp (EBAC) announced they have entered into a definitive business combination agreement. Upon closing of the transaction, the company will be named “Oculis Holding SA” and will work to accelerate the development of Oculis&rsqu